Steven Stranne

Washington, DC
Steven Stranne develops and implements regulatory, legislative and strategic initiatives for health care manufacturers, associations, providers and patient groups. He focuses on issues involving the coverage, reimbursement and coding of medical technologies and services, including drugs, biologics, devices, radiopharmaceuticals, robotics and artificial intelligence. Steve represents clients before the U.S. Congress, Centers for Medicare & Medicaid Services and the Medicare contractors, and serves as policy counsel to numerous health care providers and manufacturers of pharmaceuticals, biologics and medical devices.

Steve is a physician and lawyer with over 25 years of experience in Washington, D.C., designing and overseeing complex legislative and regulatory actions involving Congress, the Centers for Medicare & Medicaid Services (CMS), the Food and Drug Administration (FDA), numerous other federal agencies within the U.S. Department of Health and Human Services (HHS), and the Medicare Administrative Contractors.

Steve helps clients develop and implement strategies to secure appropriate reimbursement, coding, and coverage policies for new and existing medical technologies and clinical services. He also works with the boards and leadership of manufacturers, health care providers, and associations to assist with strategic planning amid the evolving regulatory and reimbursement landscape for health care services, drugs and devices. 

Steve provides unique experience in shaping public policy. He works to develop novel strategies for clients to achieve their objectives, combining his abilities to understand the health care sector and interpret and help shape clinical literature, legislation, and federal regulations. Additionally, Steve often serves as the primary contact for health care clients on a range of advocacy and legal issues, including government relations, contracting, and compliance with the federal and state laws governing fraud, abuse, and waste. He is particularly effective in discussing and presenting complex substantive issues to policy makers, including clinical issues to medical professionals within the federal agencies and Medicare contractors.


  • Harvard Law School, J.D., 1994
  • Duke University Medical School, M.D., 1990
  • Duke University, B.S.E., Mechanical Engineering, 1986

Bar and Court Admissions

  • District of Columbia


  • Chapter Co-Author, “Oncology and Health Care Policy.”  Chapter 20 in Abeloff’s Clinical Oncology, Sixth Edition, Elsevier, Inc. 2020, pages 317-336
  • Co-Author, “American Society of Clinical Oncology Policy Statement on Clinical Pathways in Oncology.” Journal of Oncology Practice. 2016 12(3):261-266
  • Author, “Health Policy Commentary: Protecting Patient Access to Oral Cancer Drugs in the United States.”  Journal of Oncology Practice.  2013 9(4):194-196
  • Co-Author, “The American Heart Association’s Recommendations for Expanding the Applications of Existing and Future Clinical Registries: A Policy Statement from the American Heart Association. Circulation. 2011 123(19):2167-2179
  • Co-Author, “American Society of Clinical Oncology Policy Statement: Opportunities in the Patient Protection and Affordable Care Act to Reduce Cancer Care Disparities.” Journal of Clinical Oncology.  2011 29: 3816-3824
  • Author, “An Oncology Perspective on Preventive Services in the Context of U.S. Healthcare Reform. Oncology. 2011 25(12):1119
  • Co-Author, “Recommendations for the Implementation of Telemedicine within Stroke Systems of Care: A Policy Statement from the American Heart Association.” Stroke. 2009 40(7):2635-2660
  • Co-Author, “The New Medicare Prescription Drug Benefit: Important Issues for Physician Practices.” Journal Medical Practice Management. 2005 21(3):133-137
  • Co-Author, “Recommendations for the Establishment of Stroke Systems of Care: Recommendations from the American Stroke Association’s Task Force on the Development of Stroke Systems.” Circulation. 2005 111(8):1078-1091
  • Co-Author, “Improving Quality of Care through Disease Management: Principles and Recommendations from the American Heart Association’s Expert Panel on Disease Management.” Circulation. 2004 109(21):2651-2654
  • Co-Author, “Recommendations for Improving the Quality of Care through Stroke Centers and Systems: An Examination of Stroke Center Identification Options.  Multidisciplinary Consensus Recommendations from the Advisory Working Group on Stroke Center Identification Options of the American Stroke Association. Stroke. 2002 33(1):e1-7
  • Co-Author, “Reforming the Legal Structure and Governance of Safety Net Health Systems.” National Association of Public Hospitals and Health Systems, Washington, D.C., June 1996
  • Co-Author, “Would Revision Arthroplasty be Facilitated by Extracorporeal Shock Wave Lithotripsy? An Evaluation including Whole Bone Strength. Clinical Orthopaedics and Related Research. 1993 287:252-258
  • Co-Author, “The Effect of Femoral Stem Geometry on Interface Motion in Uncemented Porous-Coated Total Hip Prostheses. Comparison of Straight-Stem and Curved-Stem Designs.” Journal of Bone and Joint Surgery American. 1992 74(6):839-848
  • Co-Author, “The Effect of Extracorporeal Shock Wave Lithotripsy on the Prosthesis Interface in Cementless Arthroplasty. Evaluation in a Rabbit Model.”  Journal of Arthroplasty. 1992 7(2):173-179
  • Co-Author, “Revision Arthroplasty Facilitated by Ultrasonic Tool Cement Removal. An Evaluation of Whole Bone Strength in a Canine Model.” Journal of Arthroplasty. 1992 7(4):495-500
  • Co-Author, “Screw-Augmented Fixation of Acetabular Components. A Mechanical Model to Determine Optimal Screw Placement.” Journal of Arthroplasty. 1991 6(4):301-305
  • Co-Author, “Mechanical Property Studies of Human Gallstones.”  Journal of Biomedical Materials Research. 1990 24(8):1049-1057

Foley Hoag Publications

Honors & Involvement

  • Selected for inclusion as a "Life Sciences Star" by LMG Life Sciences Magazine, 2012-2018, under categories of Health Care Pricing and Reimbursement, FDA Medical Devices and FDA Pharmaceuticals
  • Member, American Health Lawyers Association 

Speaking Engagements

  • Panel Moderator, “Key Factors for Successful Uptake of Biosimilars: Europe and the U.S.” A webinar sponsored by the Alliance for Safe Biologic Medicines and the Generics and Biosimilars Initiative, June 29, 2022.  Proceedings published in Generics and Biosimilars Initiative Journal, 2022, 11(3):112-124
  • Panel Moderator, “Non-Medical Switching of Biologicals and Biosimilars: Canada, Europe, and the U.S.” A webinar sponsored by the Alliance for Safe Biologic Medicines and the Generics and Biosimilars Initiative, July 20, 2022
  • Speaker, “Strategies for Favorable Reimbursement in the U.S. Health System.” A webinar sponsored by Swecare, the Swedish-American Chambers of Commerce, and the Embassy of Sweden in the U.S., March 23, 2021
  • Speaker, “The Affordable Care Act: Legislative Update and What to Expect in Oncology.” A presentation at the 2013 Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, June 3, 2013
  • Speaker, “Pricing Challenges and Evolving Federal Policies: Health Reform and Beyond.” A presentation at the American Conference Institutes 12th Annual National Prescription Drug Pricing Boot Camp, November 12, 2013, New York, New York
  • Speaker, “Oral Parity Legislation.” A presentation to the State Affiliate Council of the American Society of Clinical Oncology, October 11, 2012, Alexandria, Virginia
  • Co-Chair and Speaker, “In-House Counsel Forum on Medical Device Pricing and Reimbursement: A Comprehensive Guide to Current Procedures and Proposed Changes Impacting Manufacturers, and Public and Private Payers.” June 15 and 16, 2010, Chicago, Illinois, a two-day forum sponsored by American Conference Institute
  • Speaker, “Outreach to Physicians: What They Want to Know and the Limits on What You Can Tell Them.” A presentation at the Medicare Prescription Drug Part D Compliance Conference sponsored by the Health Care Compliance Association, December 13, 2005, Baltimore, Maryland